Mydecine Innovations Group Inc. (MYCO.NE)
| Previous Close | 0.1850 |
| Open | 0.1900 |
| Bid | 0.1850 x N/A |
| Ask | 0.2000 x N/A |
| Day's Range | 0.1700 - 0.1950 |
| 52 Week Range | 0.1500 - 0.6800 |
| Volume | |
| Avg. Volume | 665,616 |
| Market Cap | 46.056M |
| Beta (5Y Monthly) | 4.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2030 |
| Earnings Date | May 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. The application includes soluti
- GlobeNewswire
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety of Indications -- DENVER, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today reported its fin
- GlobeNewswire
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
DENVER, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that Dr. Rakesh Jetly, Chief Medical Officer of Mydecine, will be participating in a panel entitled, “The State of Care and the Case for Psychedelic Therapy” on Wednesday, November 10, 2021 at 7:30 p.m. on the eve of Veteran
